The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial

被引:8
|
作者
Heimburger, Sebastian M. N. [1 ,2 ,3 ]
Hoe, Bjorn [1 ,4 ]
Nielsen, Chris N. [1 ]
Bergmann, Natasha C. [1 ]
Hartmann, Bolette [3 ,5 ]
Holst, Jens J. [3 ,5 ]
Vilsboll, Tina [1 ,2 ,4 ]
Dejgaard, Thomas F. [1 ,2 ]
Christensen, Mikkel B. [1 ,4 ,6 ,7 ]
Knop, Filip K. [1 ,2 ,3 ,4 ]
机构
[1] Univ Copenhagen, Gentofte Hosp, Ctr Clin Metab Res, Hellerup, Denmark
[2] Steno Diabet Ctr Copenhagen, Gentofte, Denmark
[3] Univ Copenhagen, Fac Hlth & Med Sci, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark
[4] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark
[5] Univ Copenhagen, Fac Hlth & Med Sci, Dept Biomed Sci, Copenhagen, Denmark
[6] Univ Copenhagen, Bispebjerg Hosp, Dept Clin Pharmacol, Copenhagen, Denmark
[7] Univ Copenhagen, Bispebjerg Hosp, Copenhagen Ctr Translat Res, Copenhagen, Denmark
关键词
Adipose tissue; Continuous glucose monitoring; GIP; Glucose-dependent insulinotropic polypeptide; Glycaemic control; Glycaemic time in range; Hypoglycaemia; Hypoglycaemic events; Insulin resistance; Insulin sensitivity; RECEPTOR AGONIST; GLUCAGON; HYPOGLYCEMIA; RESPONSES;
D O I
10.1007/s00125-021-05547-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis Type 1 diabetes is characterised by reduced glucagon response to hypoglycaemia, increasing the risk of insulin treatment-associated hypoglycaemia known to hamper glycaemic control. We previously reported a glucagonotropic effect of exogenous glucose-dependent insulinotropic polypeptide (GIP) during insulin-induced hypoglycaemia in individuals with type 1 diabetes. Here we investigate the effect of a 6-day s.c. GIP infusion on time in glycaemic range as assessed by continuous glucose monitoring (CGM) in individuals with type 1 diabetes. Methods In a randomised, placebo-controlled, double-blind crossover study, time in glycaemic range (assessed by double-blinded CGM) was evaluated in 20 men with type 1 diabetes (18-75 years, stable insulin treatment >= 3 months, diabetes duration 2-15 years, fasting plasma C-peptide below 200 pmol/l, BMI 20-27 kg/m(2), HbA(1c) <69 mmol/mol [8.5%]) during two x 6 days of continuous s.c. GIP (6 pmol kg(-1) min(-1)) and placebo (saline [154 mmol/l NaCl]) infusion, respectively, with an interposed 7-day washout period. The primary outcome was glycaemic time below range, time in range and time above range. Results There were no significant differences in time below range (<3.9 mmol/l, p = 0.53) or above range (>10 mmol/l, p = 0.32) during night-time or daytime, in mean glucose, or in hypoglycaemic events as assessed by CGM. GIP altered neither self-reported hypoglycaemia nor safety measures. Compared with placebo, GIP significantly increased time in tight range (3.9-7.8 mmol/l) during daytime (06:00-23:59 hours) by [mean +/- SEM] 11.2 +/- 5.1% [95% CI 0.41, 21.9] (p = 0.02). Conclusions/interpretation Six-day s.c. GIP infusion in men with type 1 diabetes did not procure convincing effect on overall time in range, but increased time in tight glycaemic range during daytime by similar to 2 h per day.
引用
收藏
页码:2425 / 2431
页数:7
相关论文
共 50 条
  • [11] Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial
    Laursen, Jens Christian
    Sondergaard-Heinrich, Niels
    de Melo, Joana Mendes Lopes
    Haddock, Bryan
    Rasmussen, Ida Kirstine Bull
    Safavimanesh, Farzaneh
    Hansen, Christian Stevns
    Storling, Joachim
    Larsson, Henrik Bo Wiberg
    Groop, Per-Henrik
    Frimodt-Moller, Marie
    Andersen, Ulrik Bjorn
    Rossing, Peter
    ECLINICALMEDICINE, 2021, 37
  • [12] Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: a randomised, double-blind, placebo-controlled crossover trial
    Laursen, J. C.
    Heinrich, N. Sondergaard
    de Melo, J. M. L.
    Haddock, B.
    Rasmussen, I. K. B.
    Safavimanesh, F.
    Hansen, C. Stevns
    Storling, J.
    Larsson, H. B. Wiberg
    Groop, P. -H.
    Frimodt-Moller, M.
    Andersen, U. B.
    Rossing, P.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 121 - 121
  • [13] Empagliflozin reduces myocardial glucose uptake in persons with type 2 diabetes: a randomised double-blind, placebo-controlled crossover study
    Lauritsen, K. M.
    Gormsen, L. C.
    Hansen, T. K.
    Nielsen, B. R. R.
    Johannsen, M.
    Hansen, J.
    Wiggers, H.
    Botker, H. E.
    Tolbod, L. P.
    Moller, N.
    Sondergaard, E.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S62 - S62
  • [14] Effects of prebiotics on postprandial GLP-1, GLP-2 and glucose regulation in patients with type 2 diabetes: A randomised, double-blind, placebo-controlled crossover trial
    Birkeland, Eline
    Gharagozlian, Sedegheh
    Gulseth, Hanne L.
    Birkeland, Kare, I
    Hartmann, Bolette
    Holst, Jens J.
    Holst, Rene
    Aas, Anne-Marie
    DIABETIC MEDICINE, 2021, 38 (10)
  • [15] A randomised, double blind, placebo-controlled trial on the effect of Fusidin in patients with newly diagnosed Type 1 diabetes:: the FUSIDM trial
    Conget, I
    Aguilera, E
    Pellitero, S
    Näf, S
    Bendtzen, K
    Casamitjana, R
    Gomis, R
    Nicoletti, F
    DIABETOLOGIA, 2004, 47 : A293 - A293
  • [16] Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial
    Dejgaard, Thomas Fremming
    Frandsen, Christian Seerup
    Hansen, Tanja Stenbaek
    Almdal, Thomas
    Urhammer, Soren
    Pedersen-Bjergaard, Ulrik
    Jensen, Tonny
    Jensen, Andreas Kryger
    Holst, Jens Juul
    Tarnow, Lise
    Knop, Filip Krag
    Madsbad, Sten
    Andersen, Henrik Ullits
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (03): : 221 - 232
  • [17] The effect of acute morphine on obstructive sleep apnoea: a randomised double-blind placebo-controlled crossover trial
    Rowsell, Luke
    Wong, Keith K. H.
    Yee, Brendon J.
    Eckert, Danny J.
    Somogyi, Andrew A.
    Duffin, James
    Grunstein, Ronald R.
    Wang, David
    THORAX, 2019, 74 (02) : 177 - 184
  • [18] THE PHARMACOGENOMICS OF MORPHINE EFFECT ON OBSTRUCTIVE SLEEP APNEA: A RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED CROSSOVER TRIAL
    Rowsell, L.
    Yee, B.
    Wong, K.
    Somogyi, A.
    Eckert, D.
    Grunstein, R.
    Wang, D.
    JOURNAL OF SLEEP RESEARCH, 2016, 25 : 6 - 7
  • [19] Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial
    Kapitza, Christoph
    Dahl, Kirsten
    Jacobsen, Jacob B.
    Axelsen, Mads B.
    Flint, Anne
    DIABETOLOGIA, 2017, 60 (08) : 1390 - 1399
  • [20] Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial
    Christoph Kapitza
    Kirsten Dahl
    Jacob B. Jacobsen
    Mads B. Axelsen
    Anne Flint
    Diabetologia, 2017, 60 : 1390 - 1399